Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Pathophysiology

The Effects of Rosiglitazone on Insulin Sensitivity, Lipolysis, and Hepatic and Skeletal Muscle Triglyceride Content in Patients With Type 2 Diabetes

  1. Adam B. Mayerson1,
  2. Ripudaman S. Hundal1,
  3. Sylvie Dufour13,
  4. Vincent Lebon13,
  5. Douglas Befroy13,
  6. Gary W. Cline1,
  7. Staffan Enocksson1,
  8. Silvio E. Inzucchi1,
  9. Gerald I. Shulman123 and
  10. Kitt F. Petersen1
  1. 1Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut
  2. 2Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, Connecticut
  3. 3Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, Connecticut
    Diabetes 2002 Mar; 51(3): 797-802. https://doi.org/10.2337/diabetes.51.3.797
    PreviousNext
    • Article
    • Figures & Tables
    • Info & Metrics
    • PDF
    Loading

    Article Figures & Tables

    Figures

    • Tables
    • FIG. 1.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 1.

      Plasma insulin concentrations during the two-step hyperinsulinemic-euglycemic clamp before (□) and after (⧫) rosiglitazone.

    • FIG. 2.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 2.

      Effects of 3 months of rosiglitazone treatment on insulin suppression of peripheral adipocyte lipolysis during the two-step hyperinsulinemic-euglycemic clamp.

    • FIG. 3.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 3.

      Effects of 3 months of rosiglitazone treatment on hepatic triglyceride, IMLC, and EMLC content. ▪, before rosiglitazone; [cjs2113], after rosiglitazone.

    Tables

    • Figures
    • TABLE 1

      Anthropometric and fasting plasma metabolite concentrations before and after 3 months of rosiglitazone treatment

      BeforeAfterP
      Body weight (kg)92.3 ± 6.293.9 ± 5.70.34
      BMI (kg/m2)31.1 ± 1.631.9 ± 1.70.20
      Lean body mass (kg)61.3 ± 3.459.9 ± 2.50.98
      Body fat (%)29.9 ± 3.633.1 ± 4.50.78
      HbA1c (%)6.7 ± 0.4%7.2 ± 0.6%0.23
      Plasma glucose (mmol/l)9.0 ± 0.97.9 ± 0.90.02
      Insulin (pmol/l)93.6 ± 13.871.4 ± 7.80.03
      C-peptide (pmol/l)0.83 ± 0.080.76 ± 0.060.19
      Glucagon (ng/l)87.0 ± 9.083.2 ± 7.30.54
      Total cholesterol (mmol/l)4.97 ± 0.395.43 ± 0.410.09
      HDL cholesterol (mmol/l)0.88 ± 0.050.96 ± 0.050.15
      LDL cholesterol (mmol/l)2.92 ± 0.343.31 ± 0.210.14
      Triglycerides (mmol/l)6.31 ± 1.666.26 ± 1.340.97
      Fatty acids (μmol/l)497 ± 64352 ± 550.003
      Leptin (ng/ml)21.1 ± 5.718.4 ± 4.70.34
      Alkaline phosphatase (units/l)72 ± 761 ± 70.007
      γ-Glutamyl transpeptidase (units/l)29 ± 617 ± 30.001
      • Data are means ± SE.

    • TABLE 2

      Rates of glucose and lipid oxidation before and after rosiglitazone therapy

      Before rosiglitazoneAfter rosiglitazoneP
      Glucose oxidation
       Basal32.4 ± 2.338.0 ± 5.00.24
       Low-dose clamp38.0 ± 2.946.6 ± 3.20.11
       High-dose clamp71.6 ± 4.773.5 ± 3.60.68
      Lipid oxidation
       Basal158.5 ± 8.8149.7 ± 17.30.24
       Low-dose clamp138.9 ± 12.4122.1 ± 8.90.33
       High-dose clamp67.7 ± 13.771.1 ± 13.10.59
      • Data are means ± SE.

    PreviousNext
    Back to top

    In this Issue

    March 2002, 51(3)
    • Table of Contents
    • Index by Author
    Sign up to receive current issue alerts
    View Selected Citations (0)
    Print
    Download PDF
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article

    Thank you for your interest in spreading the word about Diabetes.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    The Effects of Rosiglitazone on Insulin Sensitivity, Lipolysis, and Hepatic and Skeletal Muscle Triglyceride Content in Patients With Type 2 Diabetes
    (Your Name) has forwarded a page to you from Diabetes
    (Your Name) thought you would like to see this page from the Diabetes web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    The Effects of Rosiglitazone on Insulin Sensitivity, Lipolysis, and Hepatic and Skeletal Muscle Triglyceride Content in Patients With Type 2 Diabetes
    Adam B. Mayerson, Ripudaman S. Hundal, Sylvie Dufour, Vincent Lebon, Douglas Befroy, Gary W. Cline, Staffan Enocksson, Silvio E. Inzucchi, Gerald I. Shulman, Kitt F. Petersen
    Diabetes Mar 2002, 51 (3) 797-802; DOI: 10.2337/diabetes.51.3.797

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Add to Selected Citations
    Share

    The Effects of Rosiglitazone on Insulin Sensitivity, Lipolysis, and Hepatic and Skeletal Muscle Triglyceride Content in Patients With Type 2 Diabetes
    Adam B. Mayerson, Ripudaman S. Hundal, Sylvie Dufour, Vincent Lebon, Douglas Befroy, Gary W. Cline, Staffan Enocksson, Silvio E. Inzucchi, Gerald I. Shulman, Kitt F. Petersen
    Diabetes Mar 2002, 51 (3) 797-802; DOI: 10.2337/diabetes.51.3.797
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Jump to section

    • Article
      • Abstract
      • RESEARCH DESIGN AND METHODS
      • RESULTS
      • DISCUSSION
      • Acknowledgments
      • Footnotes
      • REFERENCES
    • Figures & Tables
    • Info & Metrics
    • PDF

    Related Articles

    Cited By...

    More in this TOC Section

    • Podocyte EGFR Inhibits Autophagy Through Upregulation of Rubicon in Type 2 Diabetic Nephropathy
    • A High-Fat Diet Attenuates AMPK α1 in Adipocytes to Induce Exosome Shedding and Nonalcoholic Fatty Liver Development In Vivo
    • Multinucleated Giant Cells in Adipose Tissue Are Specialized in Adipocyte Degradation
    Show more Pathophysiology

    Similar Articles

    Navigate

    • Current Issue
    • Online Ahead of Print
    • Scientific Sessions Abstracts
    • Collections
    • Archives
    • Submit
    • Subscribe
    • Email Alerts
    • RSS Feeds

    More Information

    • About the Journal
    • Instructions for Authors
    • Journal Policies
    • Reprints and Permissions
    • Advertising
    • Privacy Policy: ADA Journals
    • Copyright Notice/Public Access Policy
    • Contact Us

    Other ADA Resources

    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • Scientific Sessions Abstracts
    • Standards of Medical Care in Diabetes
    • BMJ Open - Diabetes Research & Care
    • Professional Books
    • Diabetes Forecast

     

    • DiabetesJournals.org
    • Diabetes Core Update
    • ADA's DiabetesPro
    • ADA Member Directory
    • Diabetes.org

    © 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.